Why the APOE4 Variant Undermines Myelin and How a Lab Fix Shows Promise
Scientists at MIT’s Picower Institute for Learning and Memory have identified a molecular roadblock that explains why carriers of the APOE4 gene variant – the strongest genetic risk factor for late-onset Alzheimer’s disease – develop defective myelin, the fatty insulation that enables rapid neuronal signaling. By combining a genome-wide CRISPR screen with chromatin accessibility profiling, the team showed that APOE4 suppresses Wnt signaling in oligodendrocytes, leading to lipid-droplet buildup and impaired myelination. Restoring Wnt activity with a GSK3β inhibitor (CHIR99021) rescued myelin formation in human cell cultures, organoids, and APOE4-expressing mice, offering a proof-of-concept therapeutic avenue.
In short, APOE4 hampers the Wnt pathway in myelin-forming cells, causing lipid accumulation and weak neuronal insulation; blocking GSK3β restores the pathway and improves myelin in laboratory models.
Background: APOE4, Oligodendrocytes, and Myelin
APOE (apolipoprotein E) exists in three common isoforms – APOE2, APOE3, and APOE4. While APOE3 is considered neutral, APOE4 markedly raises the risk of Alzheimer’s disease. The brain’s white matter depends on oligodendrocytes, specialized glial cells that wrap axons with myelin, a lipid-rich sheath that speeds electrical conduction. When myelin is deficient, neural circuits slow down, contributing to cognitive decline.
Previous work from Li-Huei Tsai’s laboratory demonstrated that APOE4-carrying oligodendrocytes accumulate lipid droplets and fail to myelinate axons effectively. However, the precise signaling cascade behind this defect remained unclear, prompting the new investigation reported in Cell Stem Cell on October 15.
Unbiased CRISPR Screening Pinpoints Wnt Signaling
The researchers employed a genome-wide CRISPR knockout library to systematically delete each protein-coding gene in human APOE4 oligodendrocyte cultures. The screen revealed a striking pattern: loss of genes that normally promote Wnt signaling caused lipid-droplet accumulation, while loss of genes that inhibit Wnt also led to the same phenotype. This bidirectional result indicated that balanced Wnt activity is essential for proper lipid handling in oligodendrocytes.
“This proof of principle of doing CRISPR screens for genetic modifiers of APOE4-associated lipid accumulation in a central nervous system cell type is very exciting,” said Tsai, who also leads MIT’s Aging Brain Initiative. The screen therefore highlighted Wnt signaling as a central hub linking APOE4 to myelin defects.
Chromatin Accessibility Confirms the Pathway
In parallel, the team performed ATAC-seq (assay for transposase-accessible chromatin) on both cultured oligodendrocytes and post-mortem human brain samples, comparing APOE4 carriers to APOE3 carriers. The analysis showed that genes enhancing Wnt signaling were less accessible – i.e., more tightly packed in the genome – in APOE4 samples, while genes that dampen Wnt remained relatively open. The convergence of CRISPR and ATAC-seq data reinforced the conclusion that APOE4 suppresses Wnt activity at the transcriptional level.
Beta-Catenin, GSK3β, and the Molecular Tug-of-War
Wnt signaling hinges on the balance between beta-catenin, which activates the pathway, and glycogen-synthetase-kinase-3-beta (GSK3β), which phosphorylates beta-catenin and targets it for degradation. The MIT study found that APOE4 oligodendrocytes exhibited reduced beta-catenin expression and elevated GSK3β levels relative to APOE3 cells. This shift tips the scale toward pathway inhibition, explaining the downstream lipid-droplet buildup.
To test causality, the researchers manipulated GSK3β pharmacologically. In APOE3 cultures, adding the GSK3β activator Dif3 increased lipid droplets, mimicking the APOE4 phenotype. Conversely, treating APOE4 oligodendrocytes with the selective GSK3β inhibitor CHIR99021 dramatically reduced droplet accumulation.
Proof-of-Concept Rescue in Organoids and Mice
Beyond simple cell cultures, the team built three-dimensional brain organoids that combined APOE4 oligodendrocytes with neurons. In these more complex systems, CHIR99021 treatment not only cleared lipid droplets but also enhanced myelin formation, as evidenced by increased axon-associated magenta staining in treated organoids.
Finally, the investigators administered CHIR99021 to transgenic mice that carry human APOE4 and develop tau pathology – a hallmark of Alzheimer’s disease. Treated mice showed fewer lipid droplets in the hippocampus and a measurable increase in myelin density compared with untreated controls. These animal data provide the first in-vivo demonstration that GSK3β inhibition can counteract APOE4-driven myelin deficits.
Implications for Alzheimer’s Therapeutics
The study suggests that restoring Wnt signaling could be a viable strategy to protect white-matter integrity in APOE4 carriers. While CHIR99021 is a research-grade compound, its efficacy in multiple model systems validates GSK3β as a druggable target. Moreover, the CRISPR screen identified additional genes that modulate Wnt activity, offering a roadmap for future small-molecule or gene-therapy approaches.
Tsai notes that GSK3β also phosphorylates tau, linking two major Alzheimer’s pathologies – tau tangles and myelin loss – through a single enzyme. If a single therapeutic agent can attenuate both processes, the clinical impact could be substantial.
Key Takeaways
- APOE4 suppresses Wnt signaling in oligodendrocytes, leading to lipid-droplet buildup and poor myelination.
- A genome-wide CRISPR knockout screen and ATAC-seq analysis converged on the Wnt pathway as the critical node.
- Elevated GSK3β and reduced beta-catenin drive the signaling imbalance in APOE4 cells.
- Pharmacologic inhibition of GSK3β with CHIR99021 restores myelin in human cultures, organoids, and APOE4-expressing mice.
- The findings open new avenues for drug development targeting Wnt modulation and GSK3β activity.
Future Directions and Remaining Questions
While the proof-of-concept results are compelling, several steps remain before clinical translation. The safety profile of chronic GSK3β inhibition must be established, as the kinase participates in numerous cellular processes. Additionally, the CRISPR screen uncovered other modifiers of lipid metabolism that could be explored as adjunct targets. Long-term studies in animal models will be needed to determine whether restored myelination translates into sustained cognitive benefits.
Funding and Disclosure
The research was supported by the National Institutes of Health, the Robert and Renee E. Belfer Family Foundation, the Manthripragada McManama Alzheimer’s Fund, the CAMA Seed Fund, the J. Crayton Pruitt Foundation, Joseph P. DiSabato and Nancy Sakamoto, and the Freedom Together Foundation. Raw data are publicly available on the Open Science Framework, and the authors have filed a patent on the CRISPR screen methodology.
FAQ
What is the main function of oligodendrocytes?
Oligodendrocytes produce myelin, a lipid-rich sheath that wraps neuronal axons to accelerate electrical signaling.
How does the APOE4 variant affect these cells?
APOE4 suppresses Wnt signaling in oligodendrocytes, causing lipid droplets to accumulate instead of being incorporated into functional myelin.
What experimental technique identified the Wnt pathway as the culprit?
A genome-wide CRISPR knockout screen in human APOE4 oligodendrocyte cultures highlighted genes that regulate Wnt signaling as key modifiers of lipid accumulation.
Which protein pair regulates Wnt activity in this context?
Beta-catenin promotes Wnt signaling, while GSK3β antagonizes it by targeting beta-catenin for degradation.
What compound was used to inhibit GSK3β in the study?
The selective GSK3β inhibitor CHIR99021 reduced lipid droplets and restored myelination in both organoid and mouse models.
Did the mouse experiments show functional improvement?
The study reported reduced lipid droplets and increased myelin density in the hippocampus of treated mice, but did not assess behavioral outcomes.
Are there plans to move this therapy into human trials?
The research is currently at the proof-of-concept stage; further preclinical safety and efficacy studies are needed before clinical testing.
Conclusion
The MIT investigation provides a mechanistic link between the APOE4 allele and white-matter degeneration by exposing a Wnt-signaling deficit in oligodendrocytes. By demonstrating that GSK3β inhibition can reverse lipid accumulation and boost myelin formation, the work establishes a tangible target for future Alzheimer’s interventions. As the field moves toward precision medicine, therapies that correct such cell-type-specific pathways could become a cornerstone of personalized strategies to preserve brain health in genetically at-risk populations.
⌚ Try wearable syncing — 10 days free
Connect a tracker and get a real picture of your health right now. All data is anonymous.
